May. 31 at 7:38 PM
Attached is a schedule of all commercial-stage oncology focused bio share price changes since the XBI's recent low on 4/8/2025 (during the tariff market event) for all peers with a market cap north of
$200MM as of 5/30/25 versus the
$XBI.
$ADCT is overwhelmingly the best performer. We have no interest in @keypatience but he called it. Read his posts from around early April
$FENC has surged but has been for sale for years.
$IMCR has not traded for north of
$35 since early September 2024 after coming down from
$75 in Feb. 2024. Gains have been very recent. We're unaware of any IMCR news the last 2 weeks.
$AUTL still trades for less than cash after an impressive Q1 25 beat. Aucatzyl is expected to take major share from Tecartus in AML.
This is not investment advice.
